Filing Flows › Aytu Biopharma (AYTU) › Q3 FY25
Aytu Biopharma (AYTU) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed May 14, 2025
Aytu Biopharma (AYTU) reported revenue of $18.5M for the third quarter fiscal 2025 (Q3 FY25), +32% from a year earlier and +14% from the quarter before. Operating margin was 13.1%, net earnings $4.0M (21.6% of revenue).
Aytu Biopharma, Q3 FY25: revenue $18.5M (+32% year over year), operating margin 13.1%, net earnings $4.0M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.5M | +14% | +32% |
| Gross profit | $12.8M | +19% | +24% |
| Operating profit | $2.4M | — | — |
| Net earnings | $4.0M | +407% | — |
| Operating cash flow | −$6.5M | -322% | — |
What changed
Revenue was $18.5M in Q3 FY25, up 32% year over year and up 14% from the previous quarter.
Gross margin was 69.4%, down 4.5 points from a year earlier. Operating profit was $2.4M, a 13.1% margin (up 24.5 points year over year). Operating expenses fell 13% while revenue rose 32%. Net earnings were $4.0M. The effective tax rate was -3.2%. Non-operating items added $1.5M, 37% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.5M. Non-cash charges added back $1.3M of depreciation and amortization and $139K of share-based compensation. Working capital and other items used $11.9M. Capital expenditures of $69K exceeded it, leaving free cash flow of −$6.5M.
Questions
What was Aytu Biopharma's revenue in the third quarter fiscal 2025?
Aytu Biopharma (AYTU) reported revenue of $18.5M for the third quarter fiscal 2025 (Q3 FY25), +32% from a year earlier and +14% from the quarter before.
Was Aytu Biopharma profitable in the third quarter fiscal 2025?
Operating profit was $2.4M (13.1% of revenue) and net earnings $4.0M.
Source: Aytu Biopharma 10-Q on SEC EDGAR.